새로 진단된 표준 위험 다발성 골수종 환자에서 Daratumumab, Bortezomib, Lenalidomide 및 Dexamethasone 유도 후 Cilta-cel, Daratumumab 및 Teclistamab과 Daratumumab 병용의 다양한 순서에 대한 연구 (aMMbition)
실타카브타진 오토류셀(Cilta-cel), 다라투무맙 SC(Tal-D)와 결합한 탈케타맙 SC, 다라투무맙 SC(Tec-D)와 결합한 테크리스타맙 SC의 다양한 서열의 효능과 안전성을 평가하기 위한 2상 공개 라벨 연구 ) 새로 진단된 표준 위험 다발성 골수종 참가자에게 다라투무맙, 보르테조밉, 레날리도마이드 및 덱사메타손(DVRd) 유도 후
The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancer at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cells after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS). PFS is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Heidelberg, 독일, 69120
- Universitaetsklinikum Heidelberg
-
Tübingen, 독일, 72076
- Universitaetsklinikum Tuebingen
-
Würzburg, 독일, 97080
- Universitatsklinikum Wurzburg
-
-
-
-
California
-
Duarte, California, 미국, 91010
- City of Hope
-
San Francisco, California, 미국, 94143
- University of California San Francisco
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- University of Iowa Hospital and Clinics
-
-
New York
-
New York, New York, 미국, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28204
- Levine Cancer Institute
-
-
-
-
-
Salvador, 브라질, 41253-190
- IDOR - Regional Bahia
-
São Paulo, 브라질, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, 브라질, 05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
-
-
-
-
Madrid, 스페인, 28041
- Hosp. Univ. 12 de Octubre
-
Salamanca, 스페인, 37007
- Hosp Clinico Univ de Salamanca
-
Santander, 스페인, 39008
- Hosp. Univ. Marques de Valdecilla
-
-
-
-
-
Melbourne, 호주, 3004
- The Alfred Hospital
-
Melbourne, 호주, 3000
- Peter MacCallum Cancer Centre
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participants with documented new diagnosis of multiple myeloma (MM) according to international myeloma working group (IMWG) diagnostic criteria and with no prior myeloma-directed therapy
- Participants must have standard-risk MM (stage I and II) based on revised International Staging System (R-ISS)
- Participants must be considered fit (score equals to [=] 0) or intermediate-fit (score=1) according to IMWG Frailty Index assessment (based on the Charlson Comorbidity Index, the Katz Activity of Daily Living and the Lawson Instrumental Activities of Daily Living)
- Measurable disease defined as: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) (>=10 gram per liter [g/L] for institutions using alternative units) or urine M-protein level >= 200 milligrams per 24 hours (mg/24 hours); Light chain MM without measurable disease in the serum or the urine: Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (>=100 mg/L for institutions using alternative units) and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
Exclusion Criteria:
- Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM). Any history of malignancy, other than MM, which is considered at high risk of recurrence requiring systemic therapy
- Peripheral neuropathy or neuropathic pain of Grade >= 2, as defined by National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
- Known active or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
- Stroke or seizure within 6 months of signing the informed consent form (ICF)
- Plasma cell leukemia at the time of diagnosis or any time thereafter through apheresis (>= 5 percent [%] circulating plasma cells in peripheral blood smears), Waldenstrom macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes(POEMS) syndrome, or primary amyloid light chain amyloidosis with associated organ dysfunction
- Presence of high-risk disease features: (a) Cytogenetic high risk lesions by MM fluorescence in situ hybridization (FISH) including deletion 17p (del[17p])/, t(4;14), t(14;16), amplification 1q (amp[1q21]) (>= 4 copies); (b) Presence of 1 or more extramedullary plasmacytomas
- Seropositive for human immunodeficiency virus (HIV)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Cohort A: DVRd Induction + Tal-D Consolidation + Cilta-cel
Participants will undergo apheresis followed by 4 cycles of DVRd induction (each cycle is of 28 days) and cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release, and completion of induction, participants will begin consolidation with 4 cycles of Tal-D (each cycle is of 28 days), followed by a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days); cilta-cel will be administered 5 to 7 days after the start of the conditioning regimen. |
Talquetamab will be administered subcutaneously.
다른 이름들:
Cilta-cel infusion will be administered intravenously.
다른 이름들:
Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
다른 이름들:
Bortezomib will be administered subcutaneously as a part of induction. Lenalidomide will be administered orally as a part of induction. Dexamethasone will be administered orally as a part of induction. Cyclophosphamide will be administered intravenously as a part of conditioning regimen. Fludarabine will be administered intravenously as a part of conditioning regimen. |
|
실험적: Cohort B: DVRd Induction + Cilta-cel + Tal-D and Tec-D Consolidation
Participants will undergo apheresis followed by 4 cycles of DVRd induction and Cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release and completion of induction, participants will begin consolidation with a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days) with infusion of cilta-cel 5 to 7 days after the start of the conditioning regimen. Following cilta-cel infusion, alternating cycles of Tal-D (Cycle 1, 3, 5, and 7) and Tec-D (Cycle 2, 4, 6, and 8) will be started, no earlier than Day 84 and no later than Day 168 post cilta-cel infusion. Each cycle of Tal-D or Tec-D is 84 days which includes an extended treatment-free interval. |
Talquetamab will be administered subcutaneously.
다른 이름들:
Teclistamab will be administered subcutaneously.
다른 이름들:
Cilta-cel infusion will be administered intravenously.
다른 이름들:
Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
다른 이름들:
Bortezomib will be administered subcutaneously as a part of induction. Lenalidomide will be administered orally as a part of induction. Dexamethasone will be administered orally as a part of induction. Cyclophosphamide will be administered intravenously as a part of conditioning regimen. Fludarabine will be administered intravenously as a part of conditioning regimen. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Rate of Response with Curative Potential
기간: Up to 5 years
|
Rate of Response with curative potential is defined as the percentage of participants with a composite of durable (at least 2 years) minimal residual disease (MRD) (10^-5) negativity with complete response/stringent complete response (CR/sCR) by serology and negative positron emission tomography/computed tomography (PET/CT) imaging at 5-years after start of induction therapy. This includes: negative imaging at 5-year landmark time; MRD-negative status (at 10^-5) in 2 bone marrow examinations that are a minimum of 2 years apart; response of CR or better per the International Myeloma Working Group (IMWG) criteria; no examination showing MRD-positive status or relapse from CR in between assessments. |
Up to 5 years
|
|
Progression Free Survival (PFS) Rate at 3-Year
기간: At 3-year
|
PFS is defined as the time from the date of randomization to either progressive disease (PD), according to the IMWG response criteria, or death, whichever occurs first. |
At 3-year
|
|
PFS Rate at 5-Year
기간: At 5-year
|
PFS is defined as the time from the date of randomization to either PD, according to the IMWG response criteria, or death, whichever occurs first. |
At 5-year
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall response rate (ORR; Partial response [PR] or better)
기간: Up to 5 years
|
ORR (PR or better) is defined as the percentage of participants with best overall response of PR or better according to IMWG response criteria. |
Up to 5 years
|
|
CR or Better Rate
기간: Up to 5 years
|
Rate of CR or better is defined as the percentage of participants with best overall response of CR or better according to IMWG response criteria. |
Up to 5 years
|
|
Very Good Partial Response (VGPR) or Better Rate
기간: Up to 5 years
|
Rate of VGPR or better is defined as the percentage of participants with best overall response of VGPR or better rate according to IMWG response criteria. |
Up to 5 years
|
|
Duration of Response (DOR)
기간: Up to 5 years
|
DOR is calculated among responders (with a PR or better response) from the date of initial documented response (PR or better) to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Time to First Response (TTR)
기간: Up to 5 years
|
Time to response (that is, time to first response) is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better based on the computerized algorithm per IMWG criteria for those who had PR or better as their best response. |
Up to 5 years
|
|
Duration of CR or Better Response
기간: Up to 5 years
|
Duration of CR or better response is calculated among responders (with a CR or better response) from the date of initial documented response CR or better to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Time to First CR or Better Response
기간: Up to 5 years
|
Time to first CR or better response is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for CR or better based on the computerized algorithm per IMWG criteria. |
Up to 5 years
|
|
PFS on next line therapy (PFS2)
기간: Up to 5 years
|
PFS2 is defined as time from randomization to progression on the next line of therapy or death, whichever comes first. |
Up to 5 years
|
|
Overall Survival (OS)
기간: Up to 5 years
|
OS is measured from the date of randomization to the date of death due to any cause. |
Up to 5 years
|
|
MRD-negative CR Rate
기간: Up to 5 years
|
MRD-negative CR is defined as the percentage of participants who achieved both CR or better and MRD negativity at a threshold of 10^-5 and 10^-6. MRD-negative CR rate will be evaluated at the first occurrence from induction treatment initiation for participants per IMWG criteria. |
Up to 5 years
|
|
Number of Participants with Treatment-emergent Adverse Events (TEAEs) by Severity
기간: Up to 5 years
|
An Adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse events. |
Up to 5 years
|
|
Change from baseline in Health-related quality of life (HRQoL) (symptoms and functioning) using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 item instrument (EORTC-QLQ-C30)
기간: Up to 5 years
|
Change from baseline in participants' HRQoL (symptoms and functioning) as assessed by EORTC-QLQ-C30 will be reported. The EORTC-QLQ-C30 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, social), 1 global health status scale, 3 symptom scales (pain, fatigue, nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). The recall period is 1 week ("past week") and responses are reported using a verbal rating scale. The item and scale scores are transformed to a 0-to-100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms. |
Up to 5 years
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 혈관 질환
- 심혈관 질환
- 신생물
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 혈액 질환
- 림프 증식 장애
- 면역증식성 장애
- 신생물, 형질세포
- 지혈 장애
- 파라단백혈증
- 혈액 단백질 장애
- 출혈성 장애
- 헴 및 림프병
- 다발성 골수종
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 탄화수소
- 카르 복실 산
- 다 환식 화합물
- 파이퍼 리딘
- 무기 화학 물질
- Pretadienes
- 임신
- 스테로이드
- 융합 링 화합물
- 스테로이드, 불소
- 포스 포 아미드 머스타드
- 질소 머스타드 화합물
- 겨자 화합물
- 탄화수소, 할로겐화
- 포스 포 아미드
- 유기 인 화합물
- Pregnadienetriols
- 보 론산
- 산, 비 카르 복실
- 산
- 붕소 화합물
- 피라진
- 프탈리 미드
- 프탈산
- 산, 카르 보 사이 클릭
- 파이퍼리돈
- Isoindoles
- 레날리도마이드
- 보르테조밉
- 덱사메타손
- 시클로포스파미드
- fludarabine
- 다라 토무 맙
- 탈케타 맙
기타 연구 ID 번호
기타 연구 ID 번호
- 54767414MMY2093
- 54767414MMY2093 (기타 식별자: Janssen Research & Development, LLC)
- 2023-505792-71-00 (레지스트리 식별자: EUCT number)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .